Researchers at Kobe University reported preclinical results for off-the-shelf iPSC-derived gamma delta (γδ) T cells targeting colorectal cancer. In mouse xenograft models using patient-derived tissues, the team reported antitumor activity and described a production approach aimed at faster, cheaper scalability than autologous cell manufacturing. Published in Stem Cell Reports, the work emphasizes MHC-unrestricted targeting characteristics of γδ T cells and the ability to expand cells dramatically before use. While still preclinical, the study is positioned as a strategy to confront the manufacturing timelines and costs that constrain solid-tumor CAR-T expansion.